Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease

M. Doubková, M. Karpíšek, J. Mazoch, J. Skřičková, M. Doubek,

. 2016 ; 33 (3) : 224-234. [pub] 20161007

Jazyk angličtina Země Itálie

Typ dokumentu srovnávací studie, hodnotící studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013471

BACKGROUND: Identification of serum and bronchoalveolar lavage fluid (BALF) biomarkers may facilitate diagnosis and prognostication in various lung disorders. OBJECTIVE: Serum and BALF levels of surfactant protein A (SP-A), surfactant protein D (SP-D), Clara cell protein 16 (CC16), S100 protein, trefoil factor 3 (TFF3), and prostatic secretory protein 94 (PSP94) were evaluated in 94 consecutive patients (idiopathic pulmonary fibrosis (IPF; n=18), sarcoidosis (n=25), chronic obstructive pulmonary disease (COPD; n=51)), and in 155 healthy controls. METHODS: Biomarkers were measured at diagnosis and compared with disease characteristics. Both uniparametric and multiparametric analyses were used. RESULTS: Seven significant correlations were found: 1) BALF PSP94 level correlated with prognosis of sarcoidosis (P=0.035); 2) BALF SP-D level with pulmonary functions in IPF (P=0.032); 3) BALF SP-D and TFF3 with IPF mortality (P=0.049 and 0.017, respectively); 4) serum TFF3 level with COPD mortality (P=0.006,); 5) serum SP-A with pulmonary functions impairment in IPF (P=0.011); 6) serum SP-D level was associated with HRCT interstitial score in IPF (P=0.0346); and 7) serum SP-A was associated with staging of COPD according to spirometry (P<0.001). Moreover, our analysis showed that some biomarker levels differed significantly among the diseases: 1) BALF SP-D level differed between sarcoidosis and IPF; 2) serum SP-A level differed among IPF, sarcoidosis, COPD and was also different from healthy controls; 3) serum S100A6, S100A11 levels differed among IPF, sarcoidosis, COPD from healthy controls 4) serum SP-D, CC16, TFF-3 levels distinguished IPF patients from healthy controls; and 5) serum CC16, TFF3, PSP94 distinguished COPD patients from healthy controls. Our study shows that some of selected biomarkers should have prognostic value in the analysed lung disorders. On the other hand, these biomarkers do not appear to be unequivocally suitable for differential diagnosis of these disorders.

000      
00000naa a2200000 a 4500
001      
bmc17013471
003      
CZ-PrNML
005      
20170426093505.0
007      
ta
008      
170413s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27758987
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Doubková, Martina $u Department of Pneumology, University Hospital, Jihlavska 20, 62500 Brno. doubkovamartina@seznam.cz.
245    10
$a Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease / $c M. Doubková, M. Karpíšek, J. Mazoch, J. Skřičková, M. Doubek,
520    9_
$a BACKGROUND: Identification of serum and bronchoalveolar lavage fluid (BALF) biomarkers may facilitate diagnosis and prognostication in various lung disorders. OBJECTIVE: Serum and BALF levels of surfactant protein A (SP-A), surfactant protein D (SP-D), Clara cell protein 16 (CC16), S100 protein, trefoil factor 3 (TFF3), and prostatic secretory protein 94 (PSP94) were evaluated in 94 consecutive patients (idiopathic pulmonary fibrosis (IPF; n=18), sarcoidosis (n=25), chronic obstructive pulmonary disease (COPD; n=51)), and in 155 healthy controls. METHODS: Biomarkers were measured at diagnosis and compared with disease characteristics. Both uniparametric and multiparametric analyses were used. RESULTS: Seven significant correlations were found: 1) BALF PSP94 level correlated with prognosis of sarcoidosis (P=0.035); 2) BALF SP-D level with pulmonary functions in IPF (P=0.032); 3) BALF SP-D and TFF3 with IPF mortality (P=0.049 and 0.017, respectively); 4) serum TFF3 level with COPD mortality (P=0.006,); 5) serum SP-A with pulmonary functions impairment in IPF (P=0.011); 6) serum SP-D level was associated with HRCT interstitial score in IPF (P=0.0346); and 7) serum SP-A was associated with staging of COPD according to spirometry (P<0.001). Moreover, our analysis showed that some biomarker levels differed significantly among the diseases: 1) BALF SP-D level differed between sarcoidosis and IPF; 2) serum SP-A level differed among IPF, sarcoidosis, COPD and was also different from healthy controls; 3) serum S100A6, S100A11 levels differed among IPF, sarcoidosis, COPD from healthy controls 4) serum SP-D, CC16, TFF-3 levels distinguished IPF patients from healthy controls; and 5) serum CC16, TFF3, PSP94 distinguished COPD patients from healthy controls. Our study shows that some of selected biomarkers should have prognostic value in the analysed lung disorders. On the other hand, these biomarkers do not appear to be unequivocally suitable for differential diagnosis of these disorders.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a bronchoalveolární lavážní tekutina $x chemie $7 D001992
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a idiopatická plicní fibróza $x krev $x diagnóza $x mortalita $7 D054990
650    _2
$a plíce $x diagnostické zobrazování $x metabolismus $x patofyziologie $7 D008168
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a multivariační analýza $7 D015999
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a sekreční proteiny prostaty $x krev $7 D029584
650    _2
$a chronická obstrukční plicní nemoc $x krev $x diagnóza $x mortalita $7 D029424
650    _2
$a protein A asociovaný s plicním surfaktantem $x krev $7 D037662
650    _2
$a protein D asociovaný s plicním surfaktantem $x krev $7 D037663
650    _2
$a proteiny S100 $x krev $7 D009418
650    _2
$a plicní sarkoidóza $x krev $x diagnóza $x mortalita $7 D017565
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a spirometrie $7 D013147
650    _2
$a počítačová rentgenová tomografie $7 D014057
650    _2
$a faktor TFF3 $x krev $7 D000071165
650    _2
$a uteroglobin $x krev $7 D014598
655    _2
$a srovnávací studie $7 D003160
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
700    1_
$a Karpíšek, Michal
700    1_
$a Mazoch, Jiri
700    1_
$a Skřičková, Jana
700    1_
$a Doubek, Michael
773    0_
$w MED00177336 $t Sarcoidosis, vasculitis, and diffuse lung diseases official journal of WASOG $x 1124-0490 $g Roč. 33, č. 3 (2016), s. 224-234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27758987 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170426093823 $b ABA008
999    __
$a ok $b bmc $g 1199936 $s 974249
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 33 $c 3 $d 224-234 $e 20161007 $i 1124-0490 $m Sarcoidosis vasculitis and diffuse lung diseases $n Sarcoidosis Vasc Diffuse Lung Dis $x MED00177336
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...